New drug development war
 |
Description
Book Introduction
As we navigate the COVID-19 pandemic, we've come to naturally embrace biotechnology terms like viral antigens, mRNA vaccines, and antibody therapeutics.
However, unless you are a specialist or related person in the bio field, it is not easy to understand the specific details such as how viral antigens cause disease in our body, how antibodies fight against antigens, and what the mechanism of action of mRNA vaccines is.
"The New Drug Development War" provides easy-to-understand explanations of key terms and concepts that help readers understand the process of developing original new drugs and how they are sold and distributed in the bio market.
In addition, we introduce biotechnology that is receiving a lot of attention these days, from mRNA vaccines to CRISPR gene scissors, as well as vaccine development platforms and new dementia drugs, and biotechnology that will be in the spotlight in the future. We also diagnose the current status and problems of new drug development in the domestic bio industry, the direction to go forward, and the progress of new drug development.
This book will serve as a guide not only for those working in the bio industry responsible for the development of Korea's bio industry, but also for those majoring in related fields preparing to start a bio company or find employment, those considering investing in the pharmaceutical and biotechnology fields, and readers curious about the present and future of new drug development and biotechnology.
However, unless you are a specialist or related person in the bio field, it is not easy to understand the specific details such as how viral antigens cause disease in our body, how antibodies fight against antigens, and what the mechanism of action of mRNA vaccines is.
"The New Drug Development War" provides easy-to-understand explanations of key terms and concepts that help readers understand the process of developing original new drugs and how they are sold and distributed in the bio market.
In addition, we introduce biotechnology that is receiving a lot of attention these days, from mRNA vaccines to CRISPR gene scissors, as well as vaccine development platforms and new dementia drugs, and biotechnology that will be in the spotlight in the future. We also diagnose the current status and problems of new drug development in the domestic bio industry, the direction to go forward, and the progress of new drug development.
This book will serve as a guide not only for those working in the bio industry responsible for the development of Korea's bio industry, but also for those majoring in related fields preparing to start a bio company or find employment, those considering investing in the pharmaceutical and biotechnology fields, and readers curious about the present and future of new drug development and biotechnology.
- You can preview some of the book's contents.
Preview
index
Recommendation
prolog
Chapter 1: Basic Knowledge for Understanding New Drug Development
How are new drugs made?
New drug development process
Generics and Evergreen
biosimilars
New drug repurposing
Virtual Biotech
Chapter 2: Emerging Biotechnology
My Body's Healthy Companion_Intestinal Microbiota
Release the Brakes_Immunotherapy
Miracle Anticancer Drug_CAR-T Immune Cell Therapy
Killing instinctively_NK cells
Treating Cancer with Vaccines_Anti-Cancer Vaccines
I am ambidextrous
Safely Delivering to Cancer Cells: Radioisotope Therapy
A Non-Alcoholic Cure? _Cocktail Antibody Therapy
The protagonist of RNA innovation: mRNA vaccines
Switches that regulate mRNA_microRNA
Similar but different_organoids
Longer lasting effect
Beyond Bioenergy_Mitochondria
CRISPR gene scissors cut out only the genes I want
Chapter 3: The Future of Biotechnology
Genetic Big Data_Personalized Medicine
Liquid Biopsy: A New Window into Cancer Diagnosis
Virus Evolution VS.
Technological advancements_Coronavirus
Market Strategy for Latecomers: Vaccine Development Platform
The Last Mystery: Brain Dementia Drug
Developing New Drugs with Artificial Intelligence_Bioinformatics
Natural phenomenon VS.
Disease_Sensitive sarcopenia
Catching bacteria with viruses_bacteriophages
End the fear of needles_Microneedle patch
Chapter 4 New Drug Development in Korea
Korea's first FDA-approved new drug
The golden age of professor CEOs
Establishing a Subsidiary: Investment or a Trick?
Star CEO and planned listing
The Two Faces of Technology-Specialized Listings
Technology Exports: Good or Bad News?
Survival Strategies of Global Big Pharma
A culture of tolerance, a failure of sincerity
Fluctuations in stock prices, investing in bio stocks
Controversy over domestic vaccine technology
JP Morgan and the Everyone Plan
Survival Strategies for Startups
Why we need to start developing new drugs
Epilogue
prolog
Chapter 1: Basic Knowledge for Understanding New Drug Development
How are new drugs made?
New drug development process
Generics and Evergreen
biosimilars
New drug repurposing
Virtual Biotech
Chapter 2: Emerging Biotechnology
My Body's Healthy Companion_Intestinal Microbiota
Release the Brakes_Immunotherapy
Miracle Anticancer Drug_CAR-T Immune Cell Therapy
Killing instinctively_NK cells
Treating Cancer with Vaccines_Anti-Cancer Vaccines
I am ambidextrous
Safely Delivering to Cancer Cells: Radioisotope Therapy
A Non-Alcoholic Cure? _Cocktail Antibody Therapy
The protagonist of RNA innovation: mRNA vaccines
Switches that regulate mRNA_microRNA
Similar but different_organoids
Longer lasting effect
Beyond Bioenergy_Mitochondria
CRISPR gene scissors cut out only the genes I want
Chapter 3: The Future of Biotechnology
Genetic Big Data_Personalized Medicine
Liquid Biopsy: A New Window into Cancer Diagnosis
Virus Evolution VS.
Technological advancements_Coronavirus
Market Strategy for Latecomers: Vaccine Development Platform
The Last Mystery: Brain Dementia Drug
Developing New Drugs with Artificial Intelligence_Bioinformatics
Natural phenomenon VS.
Disease_Sensitive sarcopenia
Catching bacteria with viruses_bacteriophages
End the fear of needles_Microneedle patch
Chapter 4 New Drug Development in Korea
Korea's first FDA-approved new drug
The golden age of professor CEOs
Establishing a Subsidiary: Investment or a Trick?
Star CEO and planned listing
The Two Faces of Technology-Specialized Listings
Technology Exports: Good or Bad News?
Survival Strategies of Global Big Pharma
A culture of tolerance, a failure of sincerity
Fluctuations in stock prices, investing in bio stocks
Controversy over domestic vaccine technology
JP Morgan and the Everyone Plan
Survival Strategies for Startups
Why we need to start developing new drugs
Epilogue
Detailed image
Into the book
This book examines the efforts required to produce the fruit of a new drug in the arduous journey of new drug development, and who reaps the rewards and how.
We will also take a closer look at the areas currently receiving a lot of attention in new drug development and provide a forecast of areas that will receive more attention in the future.
We will also explore what is needed for Korea, with its limited history of new drug development, to emerge as a leader in the field.
Now, let's embark on an exciting journey together, from the birth to the death of the new drug, known as the goose that lays golden eggs.
--- p.15
Freddie Mercury, the lead vocalist of the group Queen, famous for the movie "Bohemian Rhapsody," died of AIDS in 1991.
On the other hand, American professional basketball star Magic Johnson, who went public with his AIDS diagnosis in 1991, is still living a happy life without any problems.
It was the cocktail AIDS treatment that made the difference between the lives of Freddie Mercury and Magic Johnson.
Magic Johnson, who benefited from the development of a cocktail treatment for AIDS in 1992, is still alive today, while Freddie Mercury, who did not benefit from the cocktail treatment at all, died at the young age of 45.
--- p.109
CRISPR gene scissors are a third-generation technology in the field of gene scissors.
The first generation gene scissors are zinc fingers, and the second generation gene scissors are talen.
Genetic scissors have become more accurate and have fewer side effects as they have progressed from the first generation to the second and third generations.
The side effects we talk about in gene scissors are the risk of cutting out genes other than the one we are targeting.
Of course, the third-generation CRISPR gene scissors still carry a risk of cutting genes other than the targeted gene, but it is significantly lower than the first or second-generation gene scissors.
--- p.143
Microneedles are micrometer-sized needles.
The needle size of microneedles is extremely small.
The awl-shaped microneedles are approximately 700 micrometers long.
Dozens of these tiny microneedles made into a bandage shape are called microneedle patches.
Unlike regular injections that insert liquid medicine into the body with a needle, microneedle patches, which contain freeze-dried solid medicine in a needle, are applied to the arm like a band-aid.
If you put medicine into this needle, it becomes a microneedle medicine, and if you put a vaccine into it, it becomes a microneedle vaccine.
--- p.196
Domestic biotechnology has made remarkable progress compared to the past.
However, the reality is that we are still far behind the United States, a bio powerhouse.
In the United States, various new technologies emerge at a very rapid pace.
Domestic bio scientists are struggling to keep up with new American technologies.
In this situation, developing new technologies or discovering new materials that have not yet been developed even in the United States is virtually more difficult than a camel passing through the eye of a needle.
This means that developing new drugs is that difficult and challenging.
However, it is not possible to give up on developing new drugs.
We will also take a closer look at the areas currently receiving a lot of attention in new drug development and provide a forecast of areas that will receive more attention in the future.
We will also explore what is needed for Korea, with its limited history of new drug development, to emerge as a leader in the field.
Now, let's embark on an exciting journey together, from the birth to the death of the new drug, known as the goose that lays golden eggs.
--- p.15
Freddie Mercury, the lead vocalist of the group Queen, famous for the movie "Bohemian Rhapsody," died of AIDS in 1991.
On the other hand, American professional basketball star Magic Johnson, who went public with his AIDS diagnosis in 1991, is still living a happy life without any problems.
It was the cocktail AIDS treatment that made the difference between the lives of Freddie Mercury and Magic Johnson.
Magic Johnson, who benefited from the development of a cocktail treatment for AIDS in 1992, is still alive today, while Freddie Mercury, who did not benefit from the cocktail treatment at all, died at the young age of 45.
--- p.109
CRISPR gene scissors are a third-generation technology in the field of gene scissors.
The first generation gene scissors are zinc fingers, and the second generation gene scissors are talen.
Genetic scissors have become more accurate and have fewer side effects as they have progressed from the first generation to the second and third generations.
The side effects we talk about in gene scissors are the risk of cutting out genes other than the one we are targeting.
Of course, the third-generation CRISPR gene scissors still carry a risk of cutting genes other than the targeted gene, but it is significantly lower than the first or second-generation gene scissors.
--- p.143
Microneedles are micrometer-sized needles.
The needle size of microneedles is extremely small.
The awl-shaped microneedles are approximately 700 micrometers long.
Dozens of these tiny microneedles made into a bandage shape are called microneedle patches.
Unlike regular injections that insert liquid medicine into the body with a needle, microneedle patches, which contain freeze-dried solid medicine in a needle, are applied to the arm like a band-aid.
If you put medicine into this needle, it becomes a microneedle medicine, and if you put a vaccine into it, it becomes a microneedle vaccine.
--- p.196
Domestic biotechnology has made remarkable progress compared to the past.
However, the reality is that we are still far behind the United States, a bio powerhouse.
In the United States, various new technologies emerge at a very rapid pace.
Domestic bio scientists are struggling to keep up with new American technologies.
In this situation, developing new technologies or discovering new materials that have not yet been developed even in the United States is virtually more difficult than a camel passing through the eye of a needle.
This means that developing new drugs is that difficult and challenging.
However, it is not possible to give up on developing new drugs.
--- p.271
Publisher's Review
From the concept of new drug development to the present and future of biotechnology
Bio+Economics from a Science Journalist
During the past three years, as we endured the difficult times caused by the COVID-19 pandemic, people's attention has been focused on new drug development, the pharmaceutical and biotechnology industries, and biotechnology.
Terms like antibody, antigen, and mRNA vaccine are no longer unfamiliar, and with countless people researching the pros and cons and side effects of the vaccines they are considering, understanding and interest in vaccines have naturally increased.
Moreover, the stock market was shaken every time a new bio-related stock, such as a coronavirus diagnostic kit, coronavirus vaccine, or coronavirus treatment, appeared.
Biotechnology for new drug development is one of the most promising technological fields of the future.
The Korean government also selected future automobiles, system semiconductors, and biohealth as the three key industries that will be responsible for future food.
But the winner-takes-all bio market, where only the best are remembered, is a veritable battlefield.
For Korean bio companies to become winners in the "new drug development war," they need to establish a foundation for researching innovative biotechnology and cultivate talented individuals.
Furthermore, a virtuous cycle structure is needed that allows not only professional investors but also general investors to accurately understand and invest in biotechnology trends, core technologies, and future value.
《The New Drug Development War》 clearly and easily explains the core and important terms and concepts related to new drug development.
It also presents the present and future of biotechnology, the current status and problems of new drug development in Korea, and the direction in which we should proceed.
Therefore, this book will serve as a guide not only for those working in the bio industry responsible for the development of Korea's bio industry, but also for those majoring in related fields preparing to start a bio company or find employment, those considering investing in the pharmaceutical and bio fields, and readers curious about the present and future of new drug development and biotechnology.
Winner-take-all new drug development
Who Reaps the Rewards of Blockbuster Drugs?
Everyone dreams of living a long and healthy life.
To live a healthy life, humans began to identify the causes of diseases in our bodies and search for substances that can cure them.
Before the development of science, natural products such as leaves and grass that were easily available in nature were used as medicines, but as science and technology advanced, synthetic medicines and biopharmaceuticals began to be developed.
The history of new drug development can be summed up in one word: 'humanity's ceaseless efforts to conquer disease.'
The process of developing a new drug is long and arduous, from discovering a new drug candidate, through preclinical testing (cell testing, animal testing) and clinical trials (clinical phases 1, 2, and 3), to approval and sales.
The success rate of new drug development is less than 10 percent, and the entire process of developing a new drug takes an average of 10 to 15 years and costs 1 to 2 trillion won.
But as the saying goes, 'patience is bitter, but its fruit is sweet.'
If you succeed in developing a blockbuster new drug (annual sales of over 1 trillion won) after going through countless challenges and failures, you will gain enormous wealth and fame.
Unfortunately, not all new drugs achieve the sweet fruit of being a blockbuster.
In the bio market, where only the best are remembered and only the first to survive, only the winners take all the profits.
In the arduous journey of new drug development, what efforts are required to bear fruit as a new drug, and who will ultimately reap the rewards and how? How far along are the biotech companies, struggling to be the "first," in their new drug development efforts?
Chapter 1 of "The War of New Drug Development" explains the most basic content needed to understand new drug development, including the process of creating original new drugs, generics and biosimilars that are copies of original new drugs, evergreening strategies to extend patents and exclusive sales rights, new drug repurposing, and new drug development using artificial intelligence.
The Present and Future of Biotechnology
The Evolution of Biotechnology to Become the First
As we navigate the COVID-19 pandemic, we've come to naturally embrace biotechnology terms like viral antigens, mRNA vaccines, and antibody therapeutics.
This is because the pharmaceutical and bio industries, including health, medical, and medical science, have a significant impact on our daily lives.
However, unless you are a specialist or related person in the bio field, it is not easy to understand the specific details such as how viral antigens cause disease in our body, how antibodies fight against antigens, and what the mechanism of action of mRNA vaccines is.
It is not easy to explain biotechnology based on life sciences in a way that is easy for general readers to understand.
However, author Lee Seong-gyu explains the principles and mechanisms of biotechnology in an easy-to-understand manner for general readers.
This is possible because the author is a bio-specialized journalist who majored in biotechnology at university.
Chapters 2 and 3 of “The War of New Drug Development” introduce biotechnology that is receiving a lot of attention these days, including mRNA vaccines, gut microbes, immune-oncology drugs, immune cell therapy, anticancer vaccines, cocktail antibody therapy, and CRISPR gene scissors, as well as vaccine development platforms, personalized medicine, liquid biopsy, and new dementia drugs, and explain the scientific principles by which diseases are treated.
Dreaming of developing a blockbuster new drug
domestic bio companies
Global pharmaceutical and biotech companies have successfully developed mRNA vaccines in an unprecedentedly short period of time and have reaped enormous profits amid the COVID-19 pandemic.
While global pharmaceutical companies, with full government support and corporate technological prowess, successfully developed COVID-19 vaccines, what were Korean biotech companies doing? Currently, domestic biotechnology has made remarkable progress, surpassing the past.
However, it still lags far behind compared to bio powerhouses.
For our country, with its limited history of new drug development, to emerge as a leader in this field, we must face the reality we face and devise measures to overcome our limitations.
Chapter 4 of “New Drug Development War” examines the current state of the domestic bio industry and the progress of new drug development.
Recently, interest in discovering new drug candidates has been increasing not only among traditional pharmaceutical and biotech companies, but also among universities, research institutes, and bio ventures.
However, it is also true that the technology, capital, and know-how to independently carry out the entire process of new drug development, which requires a lot of time and money, have not been accumulated.
Accordingly, there are increasing cases of bio-ventures transferring technology for new drug candidates they developed themselves overseas, but this method makes it difficult to ensure the continued growth of the domestic bio industry.
For our country to leap forward as a biopowerhouse, we must have strong government policies that support researchers and companies attempting new research, as well as the technology and know-how of bio companies capable of carrying out the entire process of new drug development.
Above all, we must properly understand the long and costly process of developing new drugs, and create a virtuous cycle of capital that allows for investment with a broad and long-term perspective.
I sincerely hope that our country can survive the competition with the world's biopowers and achieve its dream of developing a blockbuster new drug.
Bio+Economics from a Science Journalist
During the past three years, as we endured the difficult times caused by the COVID-19 pandemic, people's attention has been focused on new drug development, the pharmaceutical and biotechnology industries, and biotechnology.
Terms like antibody, antigen, and mRNA vaccine are no longer unfamiliar, and with countless people researching the pros and cons and side effects of the vaccines they are considering, understanding and interest in vaccines have naturally increased.
Moreover, the stock market was shaken every time a new bio-related stock, such as a coronavirus diagnostic kit, coronavirus vaccine, or coronavirus treatment, appeared.
Biotechnology for new drug development is one of the most promising technological fields of the future.
The Korean government also selected future automobiles, system semiconductors, and biohealth as the three key industries that will be responsible for future food.
But the winner-takes-all bio market, where only the best are remembered, is a veritable battlefield.
For Korean bio companies to become winners in the "new drug development war," they need to establish a foundation for researching innovative biotechnology and cultivate talented individuals.
Furthermore, a virtuous cycle structure is needed that allows not only professional investors but also general investors to accurately understand and invest in biotechnology trends, core technologies, and future value.
《The New Drug Development War》 clearly and easily explains the core and important terms and concepts related to new drug development.
It also presents the present and future of biotechnology, the current status and problems of new drug development in Korea, and the direction in which we should proceed.
Therefore, this book will serve as a guide not only for those working in the bio industry responsible for the development of Korea's bio industry, but also for those majoring in related fields preparing to start a bio company or find employment, those considering investing in the pharmaceutical and bio fields, and readers curious about the present and future of new drug development and biotechnology.
Winner-take-all new drug development
Who Reaps the Rewards of Blockbuster Drugs?
Everyone dreams of living a long and healthy life.
To live a healthy life, humans began to identify the causes of diseases in our bodies and search for substances that can cure them.
Before the development of science, natural products such as leaves and grass that were easily available in nature were used as medicines, but as science and technology advanced, synthetic medicines and biopharmaceuticals began to be developed.
The history of new drug development can be summed up in one word: 'humanity's ceaseless efforts to conquer disease.'
The process of developing a new drug is long and arduous, from discovering a new drug candidate, through preclinical testing (cell testing, animal testing) and clinical trials (clinical phases 1, 2, and 3), to approval and sales.
The success rate of new drug development is less than 10 percent, and the entire process of developing a new drug takes an average of 10 to 15 years and costs 1 to 2 trillion won.
But as the saying goes, 'patience is bitter, but its fruit is sweet.'
If you succeed in developing a blockbuster new drug (annual sales of over 1 trillion won) after going through countless challenges and failures, you will gain enormous wealth and fame.
Unfortunately, not all new drugs achieve the sweet fruit of being a blockbuster.
In the bio market, where only the best are remembered and only the first to survive, only the winners take all the profits.
In the arduous journey of new drug development, what efforts are required to bear fruit as a new drug, and who will ultimately reap the rewards and how? How far along are the biotech companies, struggling to be the "first," in their new drug development efforts?
Chapter 1 of "The War of New Drug Development" explains the most basic content needed to understand new drug development, including the process of creating original new drugs, generics and biosimilars that are copies of original new drugs, evergreening strategies to extend patents and exclusive sales rights, new drug repurposing, and new drug development using artificial intelligence.
The Present and Future of Biotechnology
The Evolution of Biotechnology to Become the First
As we navigate the COVID-19 pandemic, we've come to naturally embrace biotechnology terms like viral antigens, mRNA vaccines, and antibody therapeutics.
This is because the pharmaceutical and bio industries, including health, medical, and medical science, have a significant impact on our daily lives.
However, unless you are a specialist or related person in the bio field, it is not easy to understand the specific details such as how viral antigens cause disease in our body, how antibodies fight against antigens, and what the mechanism of action of mRNA vaccines is.
It is not easy to explain biotechnology based on life sciences in a way that is easy for general readers to understand.
However, author Lee Seong-gyu explains the principles and mechanisms of biotechnology in an easy-to-understand manner for general readers.
This is possible because the author is a bio-specialized journalist who majored in biotechnology at university.
Chapters 2 and 3 of “The War of New Drug Development” introduce biotechnology that is receiving a lot of attention these days, including mRNA vaccines, gut microbes, immune-oncology drugs, immune cell therapy, anticancer vaccines, cocktail antibody therapy, and CRISPR gene scissors, as well as vaccine development platforms, personalized medicine, liquid biopsy, and new dementia drugs, and explain the scientific principles by which diseases are treated.
Dreaming of developing a blockbuster new drug
domestic bio companies
Global pharmaceutical and biotech companies have successfully developed mRNA vaccines in an unprecedentedly short period of time and have reaped enormous profits amid the COVID-19 pandemic.
While global pharmaceutical companies, with full government support and corporate technological prowess, successfully developed COVID-19 vaccines, what were Korean biotech companies doing? Currently, domestic biotechnology has made remarkable progress, surpassing the past.
However, it still lags far behind compared to bio powerhouses.
For our country, with its limited history of new drug development, to emerge as a leader in this field, we must face the reality we face and devise measures to overcome our limitations.
Chapter 4 of “New Drug Development War” examines the current state of the domestic bio industry and the progress of new drug development.
Recently, interest in discovering new drug candidates has been increasing not only among traditional pharmaceutical and biotech companies, but also among universities, research institutes, and bio ventures.
However, it is also true that the technology, capital, and know-how to independently carry out the entire process of new drug development, which requires a lot of time and money, have not been accumulated.
Accordingly, there are increasing cases of bio-ventures transferring technology for new drug candidates they developed themselves overseas, but this method makes it difficult to ensure the continued growth of the domestic bio industry.
For our country to leap forward as a biopowerhouse, we must have strong government policies that support researchers and companies attempting new research, as well as the technology and know-how of bio companies capable of carrying out the entire process of new drug development.
Above all, we must properly understand the long and costly process of developing new drugs, and create a virtuous cycle of capital that allows for investment with a broad and long-term perspective.
I sincerely hope that our country can survive the competition with the world's biopowers and achieve its dream of developing a blockbuster new drug.
GOODS SPECIFICS
- Publication date: June 10, 2022
- Page count, weight, size: 272 pages | 412g | 147*217*20mm
- ISBN13: 9791188569366
- ISBN10: 1188569368
You may also like
카테고리
korean
korean
![ELLE 엘르 스페셜 에디션 A형 : 12월 [2025]](http://librairie.coreenne.fr/cdn/shop/files/b8e27a3de6c9538896439686c6b0e8fb.jpg?v=1766436872&width=3840)
